CardioInsight Gets $15M Infusion for Heart Mapping Technology

CardioInsight, an Ohio-based devicemaker specializing in mapping abnormal heart rhythms, has secured $15 million in long-term strategic financing for its noninvasive ECVUE monitoring system. The company plans to use the money to complete several clinical trials in Europe, advance product development and pursue regulatory clearance in the U.S.

The ENVUE system is comprised of a vest with 250 electrodes, which the patient wears during multiple tests that analyze cardiac rhythm. The results are then combined with a CT scan to create a complete, real-time map of electrical activity in the heart.

The platform has been used in more than 800 people in multiple locations and across multiple types of arrhythmia, the company said.

“This is an important financing transaction for the company as it provides the resources necessary to accelerate and achieve key milestones in the continued evolution of the company’s revolutionary noninvasive, multiple chamber cardiac mapping technology,” said President and CEO Patrick Wethington.

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.